Through pioneering work in developing and producing isotopes like iodine-125, lutetium-177 and holmium-166, scientists at McMaster University are advancing next-generation radiopharmaceuticals that make cancer treatment more targeted and effective.
By expanding the capacity of the McMaster Nuclear Reactor, researchers are using advanced nuclear methods to produce isotopes that enable radiation to target cancer cells more precisely, reducing side effects, improving recovery times and transforming patient care. The reactor, Canada’s largest, already produces 60 per cent of the world’s iodine-125, an isotope used in therapies for prostate and other cancers.
With spin-outs such as Fusion Pharmaceuticals and AtomVie Global Radiopharma, McMaster’s research is moving life-saving therapies from the lab to hospitals around the world. This work not only strengthens health outcomes but also positions Ontario as a global hub for medical isotope innovation.
For more information, visit McMaster University.
